Quantcast

Latest Interferon Stories

2014-09-17 08:29:05

DUBLIN, Sept. 17, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Hepatitis C Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Hepatitis C is a liver disease caused by infection due to hepatitis C virus. Hepatitis C infection predominantly affects the liver; however, other parts of the body are also affected such as the brain and the digestive system. Hepatitis C virus is an RNA virus belonging to the family...

2014-09-16 08:32:04

HOUSTON, Sept. 16, 2014 /PRNewswire/ -- DNAtrix, Inc., experts in oncolytic virus development, today announced that the first patient was treated with the company's lead product, DNX-2401, a replication competent adenovirus plus gamma interferon in a randomized, multicenter, open-label Phase Ib study for patients with recurrent glioblastoma. "DNAtrix, in collaboration with leading neurosurgeons and neuro-oncologists in the US, is pleased to announce the initiation of our randomized...

2014-09-09 04:21:06

~Convening World's Leading Researchers in MS with a Program Covering all Aspects of Research Including Cause and Pathology, Genetics and Environmental Impact, Emerging Treatment Study Findings and Nervous System Repair BOSTON, Sept. 9, 2014 /PRNewswire/ -- On September 10-13 at the Hynes Convention Center in Boston, MA, ACTRIMS-ECTRIMS will host their joint triennial international meeting - MSBoston 2014, with over 8,000 participant from leading organizations in Europe, North America and...

2014-09-04 16:27:48

FLINT, Mich., Sept. 4, 2014 /PRNewswire/ -- Diplomat, the nation's largest independent specialty pharmacy, announced that it will distribute Plegridy(TM) (peginterferon beta-1a). Manufactured by Biogen Idec, Plegridy(TM) was approved on August 15, 2014 by the US Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis (RMS). Plegridy is the only pegylated beta interferon approved for use in RMS and is dosed once every two weeks. Plegridy can be...

2014-09-02 08:31:32

ROCKLAND, Mass., Sept. 2, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that Drew Young has joined the company as Senior Vice President, Neurology and Immunology. In this capacity, he will be responsible for leading the strategic direction of the U.S. Neurology and Immunology franchise, including future products. http://photos.prnewswire.com/prnvar/20140902/141784 Bringing more than 20 years of experience leading global and...

2014-08-25 08:28:14

WOONSOCKET, R.I., Aug. 25, 2014 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC: MCET) has been issued U.S. patent 8,809,290 covering novel drug compositions and platform technologies which redirect the immune system response to protect against highly virulent virus infection and cancer. These novel drug compositions consisting of noncoding doubled stranded RNA (dsRNA) molecules and recombinant immunoglobulin-peptide (IgP) molecules demonstrate unique immune stimulating activity,...

Early Step In Body's Counterattack On Virus Blocked By Ebola Protein
2014-08-15 03:16:59

The Mount Sinai Hospital / Mount Sinai School of Medicine Findings provide framework for new drug development efforts One of the human body's first responses to a viral infection is to make and release signaling proteins called interferons, which amplify the immune system response to viruses. Over time, many viruses have evolved to undermine interferon's immune-boosting signal, and a paper published today in the journal Cell Host & Microbe describes a mechanism unique to the Ebola...

2014-07-29 23:13:49

San Antonio researcher leads national study that identified a combination of pills that cures 9 of 10 hepatitis C patients. San Antonio, TX (PRWEB) July 29, 2014 Researchers from The University of Texas Health Science Center at San Antonio, the Texas Liver Institute and other institutions have identified a combination of pills that cures 9 of 10 hepatitis C patients. The combination of the drugs sofosbuvir and simeprevir, with or without ribavirin, cured 93 percent of patients in 12...

2014-07-21 11:07:15

The JAMA Network Journals HIV-infected patients also infected with hepatitis C virus (HCV) who received a combination of the medications sofosbuvir plus ribavirin had high rates of sustained HCV virologic response 12 weeks after cessation of therapy, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. The issue is being released early to coincide with the International AIDS Conference. Up to 7 million persons worldwide are infected with both human...

2014-07-15 12:28:37

Unprecedented Growth Will be Fuelled by Rapid Uptake of All-Oral, Interferon-Free Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., July 15, 2014 /PRNewswire/ -- Decision Resources Group finds that the hepatitis C virus (HCV) population is large with more than 2 million diagnosed, chronically infected cases throughout the G7 markets (United States, France, Germany, Italy, Spain, United Kingdom and Japan). Many of these patients, including more than 270,000 with...


Latest Interferon Reference Libraries

0_9255b919f71eff1fd4202c1dbb1795d2
2011-01-12 15:49:29

Hepadnaviruses can cause liver infections in humans and animals. The two recognized genera are Genus Orthohepadnavirus and Genus Avihepadnavirus. It has a small genome of partially double-stranded, partially single stranded circular DNA. It is a group 7 virus that uses an RNA intermediate during replication. Most people who come into contact with the virus are able to clear the infection alone although some cannot and usually progress to fulminant hepatitis. It can cause sever liver...

More Articles (1 articles) »
Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related